Now Is the Time for Perioperative Chemotherapy in Upper Tract Urothelial Cancer.

[1]  Steven L. Chang,et al.  EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY AFTER RADICAL NEPHROURETERECTOMY FOR LOCALLY ADVANCED AND/OR POSITIVE REGIONAL LYMPH NODE UPPER TRACT UROTHELIAL CARCINOMA: MP71‐09 , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[3]  R. Millikan,et al.  A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. , 2016, European urology.

[4]  N. Schultz,et al.  Genomic Characterization of Upper Tract Urothelial Carcinoma. , 2015, European urology.

[5]  Steven L. Chang,et al.  A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. , 2014, European urology.

[6]  V. Margulis,et al.  Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma , 2014, Cancer.

[7]  Katherine A. Hoadley,et al.  Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology , 2014, Proceedings of the National Academy of Sciences.

[8]  K. Baggerly,et al.  Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. , 2014, Cancer cell.

[9]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[10]  David A. Green,et al.  Urothelial carcinoma of the bladder and the upper tract: disparate twins. , 2013, The Journal of urology.

[11]  G. Sonpavde,et al.  A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. , 2011, The Lancet. Oncology.

[12]  R. Millikan,et al.  Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high‐risk upper tract transitional cell carcinoma , 2010, Cancer.

[13]  H. Lynch,et al.  Extracolonic cancer in hereditary nonpolyposis colorectal cancer , 1993, Cancer.

[14]  L. Collette,et al.  Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. , 2015, The Lancet. Oncology.